As of Jan 17
| -0.20 / -0.50%|
The 12 analysts offering 12-month price forecasts for Pacira Pharmaceuticals Inc have a median target of 44.00, with a high estimate of 89.00 and a low estimate of 34.00. The median estimate represents a +11.39% increase from the last price of 39.50.
The current consensus among 13 polled investment analysts is to Buy stock in Pacira Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.